热门资讯> 正文

Geron strategic restructuring plan focuses on Rytelo growth

2025-12-17 06:49

杰龙(GERN) 0

Geron said that as part of its strategic restructuring plan, it will focus on boosting growth of anemia treatment Rytelo (imetelestat) in the US, expanding availability of the drug into other countries, and a phase 3 program of imetelestat in myelofibrosis.
Earlier in December, the company said it would lay off a third of its 260 employees as part of the plan.

More on Geron

Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help
Geron Corporation (GERN) Q3 2025 Earnings Call Transcript
Geron to lay off a third of workforce under restructuring program
Geron signals 2026 growth focus as RYTELO new patient starts rise to 36% in Q3

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。